Characteristics of Sweet's syndrome associated with novel acute myeloid leukemia targeted drugs—Midostaurin and Enasidenib

Sweet’s syndrome is an acute febrile neutrophilic dermatosis which can be associated with anticancer drugs. Herein we report two cases of Sweet’s syndrome in association with recently approved drugs for acute myeloid leukemia: FLT3 inhibitor Midostaurin and IDH 2 inhibitor Enasidenib. In both cases, there was temporal association between initiation of drug and development of characteristic clinical features and biopsy findings consistent with Sweet’s syndrome. Improvement in symptoms with initiation of steroids and eventual resolution with prednisone taper further strengthened suspicion for drug‐induced Sweet’s syndrome.